Sign in

    Max Star • Goldman Sachs

    No publicly available information could be found confirming the existence of Max Star as an analyst or employee at Goldman Sachs. There is no record of a professional profile, LinkedIn presence, analyst performance metrics, specific company coverage, or recognized credentials associated with that name at Goldman Sachs or on major industry platforms. Without verifiable sources, a comprehensive professional profile cannot be created for Max Star at this time.

    Max Star's questions to CureVac NV (CVAC) leadership

    Max Star's questions to CureVac NV (CVAC) leadership • Q4 2024

    Question

    Max Star, on behalf of Rajan Sharma, asked about the expected progression of R&D costs in 2025 and the design of the lung cancer trial regarding response rate assessment. He also questioned the decline in mRNA integrity shown in the LNP stability data.

    Answer

    CFO Axel-Sven Malkomes noted that while R&D spending will support pipeline advancement, the company remains focused on cost efficiencies. CSO Myriam Mendila confirmed the lung cancer trial will measure for tumor shrinkage and other efficacy endpoints after adding the vaccine to patients stable on pembrolizumab. She clarified that the mRNA integrity shown in the stability data after 12 months at room temperature remains within regulatory specifications.

    Ask Fintool Equity Research AI

    Max Star's questions to CureVac NV (CVAC) leadership • Q4 2024

    Question

    Asked about the outlook for R&D costs in 2025, the clinical trial design for measuring response in the lung cancer trial, and the mRNA stability data presented.

    Answer

    R&D costs will be focused on the core pipeline while the company continues to seek cost efficiencies. In the lung cancer trial, patients stable on pembrolizumab will receive the vaccine, and efficacy will be measured by tumor response, progression-free survival, and other endpoints. The observed decline in mRNA integrity at room temperature after one year is still within regulatory specifications and considered encouraging.

    Ask Fintool Equity Research AI